CA2674369C - Fused substituted aminopyrrolidine derivative - Google Patents

Fused substituted aminopyrrolidine derivative Download PDF

Info

Publication number
CA2674369C
CA2674369C CA2674369A CA2674369A CA2674369C CA 2674369 C CA2674369 C CA 2674369C CA 2674369 A CA2674369 A CA 2674369A CA 2674369 A CA2674369 A CA 2674369A CA 2674369 C CA2674369 C CA 2674369C
Authority
CA
Canada
Prior art keywords
group
formula
salt
compound
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2674369A
Other languages
English (en)
French (fr)
Other versions
CA2674369A1 (en
Inventor
Hisashi Takahashi
Satoshi Komoriya
Takahiro Kitamura
Takashi Odagiri
Hiroaki Inagaki
Toshifumi Tsuda
Kiyoshi Nakayama
Makoto Takemura
Kenichi Yoshida
Rie Miyauchi
Masatoshi Nagamochi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CA2674369A1 publication Critical patent/CA2674369A1/en
Application granted granted Critical
Publication of CA2674369C publication Critical patent/CA2674369C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA2674369A 2007-01-05 2007-12-28 Fused substituted aminopyrrolidine derivative Expired - Fee Related CA2674369C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2007-000667 2007-01-05
JP2007000667 2007-01-05
JP2007074991 2007-03-22
JP2007-074991 2007-03-22
PCT/JP2007/075434 WO2008082009A2 (en) 2007-01-05 2007-12-28 Fused substituted aminopyrrolidine derivative

Publications (2)

Publication Number Publication Date
CA2674369A1 CA2674369A1 (en) 2008-07-10
CA2674369C true CA2674369C (en) 2012-04-03

Family

ID=39522355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2674369A Expired - Fee Related CA2674369C (en) 2007-01-05 2007-12-28 Fused substituted aminopyrrolidine derivative

Country Status (24)

Country Link
US (2) US8618094B2 (cg-RX-API-DMAC7.html)
EP (2) EP2540715A1 (cg-RX-API-DMAC7.html)
JP (1) JP5197606B2 (cg-RX-API-DMAC7.html)
KR (1) KR101419085B1 (cg-RX-API-DMAC7.html)
AR (1) AR064753A1 (cg-RX-API-DMAC7.html)
AU (1) AU2007339692B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0720771A2 (cg-RX-API-DMAC7.html)
CA (1) CA2674369C (cg-RX-API-DMAC7.html)
CL (1) CL2008000026A1 (cg-RX-API-DMAC7.html)
CY (1) CY1114444T1 (cg-RX-API-DMAC7.html)
DK (1) DK2097400T3 (cg-RX-API-DMAC7.html)
ES (1) ES2428344T3 (cg-RX-API-DMAC7.html)
IL (1) IL199694A (cg-RX-API-DMAC7.html)
MX (1) MX2009007291A (cg-RX-API-DMAC7.html)
MY (1) MY162052A (cg-RX-API-DMAC7.html)
NO (1) NO20092804L (cg-RX-API-DMAC7.html)
NZ (1) NZ577214A (cg-RX-API-DMAC7.html)
PE (1) PE20081631A1 (cg-RX-API-DMAC7.html)
PL (1) PL2097400T3 (cg-RX-API-DMAC7.html)
PT (1) PT2097400E (cg-RX-API-DMAC7.html)
RU (1) RU2443698C2 (cg-RX-API-DMAC7.html)
SI (1) SI2097400T1 (cg-RX-API-DMAC7.html)
TW (1) TWI409068B (cg-RX-API-DMAC7.html)
WO (1) WO2008082009A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2602253A4 (en) 2010-08-06 2014-01-01 Daiichi Sankyo Co Ltd CRYSTAL OF AN ANTIBACTERIAL CONNECTION
WO2014152317A2 (en) * 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating gonorrhea infections using quinolone antibiotics
CN113666938A (zh) 2016-02-12 2021-11-19 细胞动力学股份有限公司 四氢异喹啉衍生物
CN114008031A (zh) * 2019-10-23 2022-02-01 太景生物科技股份有限公司 喹诺酮羧酸衍生物
CA3227204A1 (en) * 2021-07-22 2023-01-26 The Texas A&M University System Activated ferrate solutions and methods thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61282382A (ja) 1985-06-06 1986-12-12 Dainippon Pharmaceut Co Ltd フエニル置換１，８−ナフチリジン誘導体、そのエステルおよびその塩
EP0242789A3 (en) 1986-04-25 1990-09-05 Dainippon Pharmaceutical Co., Ltd. Novel quinoline derivates and processes for preparation thereof
JPH0676400B2 (ja) 1987-08-25 1994-09-28 大日本製薬株式会社 新規ピリドンカルボン酸誘導体、そのエステルおよびその塩
MY105136A (en) 1988-04-27 1994-08-30 Daiichi Seiyaku Co Optically active pyridonecarboxylic acid derivatives.
JP2844079B2 (ja) * 1988-05-23 1999-01-06 塩野義製薬株式会社 ピリドンカルボン酸系抗菌剤
JP2807277B2 (ja) 1988-08-31 1998-10-08 第一製薬株式会社 スピロ化合物
JPH0278659A (ja) * 1988-09-12 1990-03-19 Shionogi & Co Ltd アザビシクロアルカン類化合物
EP0677522A4 (en) 1992-12-28 1995-12-27 Yoshitomi Pharmaceutical 8-METHOXYCHINOLONE CARBONIC ACID DERIVATIVES.
JPH06345261A (ja) 1993-04-16 1994-12-20 Daihen Corp 自動搬送装置の搬送用ハンド
DK0812838T3 (da) * 1994-02-04 2002-08-19 Dainippon Pharmaceutical Co Pyridoncarboxylsyrederivater substitueret med bicyclisk aminogruppe, estere og salte deraf og bicyclisk amin som mellemprodukt
DE4435479A1 (de) 1994-10-04 1996-04-11 Bayer Ag Chinolon- und Naphthyridoncarbonsäure-Derivate
PT807630E (pt) * 1995-02-02 2003-08-29 Daiichi Seiyaku Co Compostos heterociclicos
JPH11510478A (ja) * 1995-06-06 1999-09-14 アボツト・ラボラトリーズ キノリジノン型化合物
JP4132155B2 (ja) * 1996-10-25 2008-08-13 第一三共株式会社 三環性アミン誘導体
ID28795A (id) * 1998-11-24 2001-07-05 Daiichi Seiyaku Co Turunan aminometilpirolidina tersubstitusi sikloalkil
HUP0400652A2 (hu) * 2000-11-24 2004-06-28 Meiji Seika Kaisha Ltd. Új karbapenemszármazékok és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
WO2005049602A1 (en) * 2003-11-18 2005-06-02 Warner-Lambert Company Llc Quinolone antibacterial agents
US7563805B2 (en) * 2005-05-19 2009-07-21 Daiichi Pharmaceutical Co., Ltd. Tri-, tetra-substituted-3-aminopyrrolidine derivative

Also Published As

Publication number Publication date
KR101419085B1 (ko) 2014-07-15
EP2097400B1 (en) 2013-07-03
SI2097400T1 (sl) 2013-10-30
KR20090096618A (ko) 2009-09-11
US8618094B2 (en) 2013-12-31
HK1130056A1 (en) 2009-12-18
RU2009129975A (ru) 2011-02-10
BRPI0720771A2 (pt) 2014-07-15
AU2007339692A1 (en) 2008-07-10
ES2428344T3 (es) 2013-11-07
IL199694A (en) 2013-08-29
JP2010515663A (ja) 2010-05-13
JP5197606B2 (ja) 2013-05-15
IL199694A0 (en) 2010-04-15
MX2009007291A (es) 2009-07-14
NZ577214A (en) 2011-11-25
CL2008000026A1 (es) 2008-05-16
CA2674369A1 (en) 2008-07-10
CY1114444T1 (el) 2016-08-31
RU2443698C2 (ru) 2012-02-27
AU2007339692B2 (en) 2012-01-19
EP2097400A2 (en) 2009-09-09
PL2097400T3 (pl) 2013-11-29
MY162052A (en) 2017-05-31
AR064753A1 (es) 2009-04-22
PE20081631A1 (es) 2008-11-22
US20120108582A1 (en) 2012-05-03
DK2097400T3 (da) 2013-10-14
TWI409068B (zh) 2013-09-21
US20130029977A9 (en) 2013-01-31
TW200836733A (en) 2008-09-16
NO20092804L (no) 2009-10-05
WO2008082009A3 (en) 2008-12-11
EP2540715A1 (en) 2013-01-02
PT2097400E (pt) 2013-10-10
WO2008082009A2 (en) 2008-07-10
US20140142096A1 (en) 2014-05-22

Similar Documents

Publication Publication Date Title
JP5475841B2 (ja) トリ−、テトラ−置換−３−アミノピロリジン誘導体
CA2674369C (en) Fused substituted aminopyrrolidine derivative
CN101622240B (zh) 稠合取代氨基吡咯烷衍生物
US6384050B1 (en) Tricyclic amine derivatives
US8455482B2 (en) Substituted pyrrolidine derivative
US20040063754A1 (en) Dehalogeno compounds
NO321528B1 (no) Cykloalkyl-substituerte aminometylpyrrolidin-derivater, og antibakterielle midler inneholdende slike forbindelser
JPWO1998054169A1 (ja) 置換シクロブチルアミン誘導体
JP2010031000A (ja) フューズ置換型アミノピロリジン誘導体含有医薬組成物
JP5063032B2 (ja) トリ−、テトラ−置換−３−アミノピロリジン誘導体
HK1130056B (en) Fused substituted aminopyrrolidine derivative
JPWO2005073238A1 (ja) ピリドベンズオキサジン誘導体
JPH1112278A (ja) ピリドンカルボン酸誘導体、そのエステルまたはこれらの塩

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20151229